EZH2 and hepatocellular carcinoma: Given the higher expression levels of EZH2, G6PD, CBX8, NDRG1 in the high risk score scroe group of HCC patients, we speculate that targeting cellular senescence to treat HCC may have a better therapeutic effects for such patients.